According to the research report, the global prostate cancer market size is expected to touch USD 28.37 Billion by 2032, from USD 12.07 Billion in 2022, growing with a significant CAGR of 8.92% from 2023 to 2032.
The prostate cancer report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global prostate cancer in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global prostate cancer market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global prostate cancer during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2964
This study covers a detailed segmentation of the global prostate cancer market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global prostate cancer market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- AbbVie, Inc.
- Astellas Pharma, Inc.
- AstraZeneca plc
- Bayer AG
- Clovis Oncology, Inc.
- Dendreon Pharmaceuticals LLC
- Ferring Pharmaceuticals
- Johnson & Johnson (Janssen)
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
Market Segmentation
By Drug Class
- Hormonal ADT
- AR-Directed Therapies
- Cytotoxic agents
- Bone metastases
- therapeutic vaccines
- PARP inhibitors
- Kinase inhibitors
- PSMA-targeted radioligands
By Distribution Channel
- Hospital Pharmacies
- Drug store & Retail pharmacies
- Online pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global prostate cancer report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global prostate cancer market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Prostate Cancer Market
5.1. COVID-19 Landscape: Prostate Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Prostate Cancer Market, By Drug Class
8.1. Prostate Cancer Market Revenue and Volume, by Drug Class, 2023-2032
8.1.1. Hormonal ADT
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. AR-Directed Therapies
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Cytotoxic agents
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Bone metastases
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. therapeutic vaccines
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. PARP inhibitors
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
8.1.7. Kinase inhibitors
8.1.7.1. Market Revenue and Volume Forecast (2020-2032)
8.1.8. PSMA-targeted radioligands
8.1.8.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Prostate Cancer Market, By Distribution Channel
9.1. Prostate Cancer Market Revenue and Volume, by Distribution Channel, 2023-2032
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Drug store & Retail pharmacies
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Online pharmacies
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Prostate Cancer Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 11. Company Profiles
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Astellas Pharma, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca p
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Clovis Oncology, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dendreon Pharmaceuticals LLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Ferring Pharmaceuticals
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Johnson & Johnson (Janssen)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments